April 12th 2024
Data showed that 87.8% of treated patients and 96.1% of patients who completed the study achieved normal 24-hour mean plasma testosterone values (222 to 800 ng/dL) at 90-day follow-up.
September 28th 2023
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Targeted PET imaging shows promise in prostate Ca
June 1st 2015A novel compound used with positron emission tomography imaging can identify foci of prostate cancer not found on biopsy of the prostate pre surgery or on the post-surgery specimen, according to a pilot study presented at the American Association of Cancer Research annual meeting in Philadelphia.
Dr. Google creates anxiety, opportunity
June 1st 2015Most health information seekers navigate the Internet for what they think will be the best information available about their health condition or that of a loved one. Unfortunately, the Internet is unfiltered, unregulated, and often saturated with promotional, unsubstantiated, and at times frightening information.
Promoting TRT online: Balanced information lacking
June 1st 2015Patients taking to the Internet for information about testosterone replacement therapy are likely getting an incomplete picture of the potential risks and adverse effects linked with the treatment, say researchers from Northwestern University Feinberg School of Medicine, Chicago, and the University of Pennsylvania, Philadelphia.
BPH technique efficacious even in severe obstruction
May 1st 2015A patient follow-up report shows promising mid-term results from five German urology centers that implemented the prostatic urethral lift (UroLift System, NeoTract, Inc.) to alleviate symptomatic BPH in patients suffering from mild, moderate, and even severe obstruction.
Biomarkers yet to fully justify claimed clinical utility
May 1st 2015Biomarker models to predict disease progression in prostate cancer have a promising future, but at present, they have not fully justified their claimed clinical utilities, according to the authors of an independent review and analysis of the literature.
Study supports BPH laser’s use in high-risk men
May 1st 2015Laser photoselective vaporization prostatectomy using a 180W 532-nm lithium triborate laser (GreenLight XPS-180W laser system, American Medical Systems) is a safe and efficient option for treating BPH in men at high risk for surgical complications, according to findings from a large, international retrospective analysis.
Injected TRT earns high marks for safety, effectiveness
April 29th 2015A newly published review suggests that age-related testosterone deficiency treatment with intramuscular injections of testosterone replacement therapy offers health benefits and lower cardiovascular risk compared to testosterone replacement by patch or gel.
Allograft wrap helps restore post-RP continence, potency
April 29th 2015Placement of a nerve “wrap” around the neurovascular bundle during nerve-sparing robot-assisted radical prostatectomy appears to accelerate the early restoration of continence and potency following surgery, a recently published study has shown.